Hiroo Katsuya

1.6k total citations
57 papers, 536 citations indexed

About

Hiroo Katsuya is a scholar working on Immunology, Ecology, Evolution, Behavior and Systematics and Oncology. According to data from OpenAlex, Hiroo Katsuya has authored 57 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 15 papers in Ecology, Evolution, Behavior and Systematics and 12 papers in Oncology. Recurrent topics in Hiroo Katsuya's work include T-cell and Retrovirus Studies (23 papers), Vector-Borne Animal Diseases (15 papers) and Animal Disease Management and Epidemiology (9 papers). Hiroo Katsuya is often cited by papers focused on T-cell and Retrovirus Studies (23 papers), Vector-Borne Animal Diseases (15 papers) and Animal Disease Management and Epidemiology (9 papers). Hiroo Katsuya collaborates with scholars based in Japan, United Kingdom and United States. Hiroo Katsuya's co-authors include Kenji Ishitsuka, Yorifumi Satou, Paola Miyazato, Kazuo Tamura, Misaki Matsuo, Junji Suzumiya, Yasushi Takamatsu, Kazuo Tamura, Hidenori Sasaki and Saiful Islam and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hiroo Katsuya

55 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroo Katsuya Japan	14	242	148	136	120	111	57	536
Francisco Santiago United States	10	249 1.0×	168 1.1×	135 1.0×	131 1.1×	77 0.7×	13	487
Ambroise Marçais France	16	453 1.9×	101 0.7×	227 1.7×	239 2.0×	146 1.3×	53	725
Jida Choi South Korea	16	371 1.5×	148 1.0×	62 0.5×	233 1.9×	248 2.2×	41	899
Takeaki Tomoyose Japan	13	316 1.3×	48 0.3×	163 1.2×	132 1.1×	59 0.5×	37	561
Nora‐Athina Viniou Greece	14	105 0.4×	299 2.0×	17 0.1×	22 0.2×	165 1.5×	64	789
Ariel Isaacs Australia	12	325 1.3×	135 0.9×	17 0.1×	26 0.2×	133 1.2×	25	658
Ikuo Kikuchi Japan	9	183 0.8×	53 0.4×	39 0.3×	36 0.3×	21 0.2×	34	424
Vidyanath Chaudhary Hong Kong	11	214 0.9×	166 1.1×	49 0.4×	7 0.1×	53 0.5×	17	516
Hiroo Inouye Japan	13	355 1.5×	50 0.3×	36 0.3×	37 0.3×	70 0.6×	34	599
Οlga Benopoulou Greece	8	79 0.3×	83 0.6×	14 0.1×	19 0.2×	121 1.1×	16	394

Countries citing papers authored by Hiroo Katsuya

Since Specialization

Citations

This map shows the geographic impact of Hiroo Katsuya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroo Katsuya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroo Katsuya more than expected).

Fields of papers citing papers by Hiroo Katsuya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroo Katsuya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroo Katsuya. The network helps show where Hiroo Katsuya may publish in the future.

Co-authorship network of co-authors of Hiroo Katsuya

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroo Katsuya. A scholar is included among the top collaborators of Hiroo Katsuya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroo Katsuya. Hiroo Katsuya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Katsuya, Hiroo, et al.. (2025). Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling. Frontiers in Immunology. 16. 1549452–1549452. 2 indexed citations

Tsuji, Akihito, Yu Sunakawa, Manabu Shiozawa, et al.. (2025). Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).. Journal of Clinical Oncology. 43(4_suppl). 17–17. 1 indexed citations

Fukushima, Takuya, Kunihiro Tsukasaki, Ryunosuke Machida, et al.. (2024). Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 7001–7001. 1 indexed citations

Kubota, Yasushi, Sho Okamoto, Hiroshi Ureshino, et al.. (2024). Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report. Annals of Hematology. 104(1). 821–828.

Kito, Yosuke, Hisato Kawakami, Seiichiro Mitani, et al.. (2023). Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The Oncologist. 29(3). e330–e336. 5 indexed citations

Ureshino, Hiroshi, Makoto Fukuda, Mariko Miyazaki, et al.. (2023). Type II Cryoglobulinemic Membranoproliferative Glomerulonephritis Caused by Mucosa-associated Lymphoid Tissue Lymphoma. Internal Medicine. 62(13). 1983–1988. 1 indexed citations

Suyama, Koichi, Hiroo Katsuya, Naoki Izawa, et al.. (2022). A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. European Journal of Cancer. 166. 279–286. 4 indexed citations

Matsuo, Misaki, Takaharu Ueno, Kazuaki Monde, et al.. (2022). Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nature Communications. 13(1). 2405–2405. 24 indexed citations

Hirata, Kenro, Yasuo Hamamoto, Hirokazu Shoji, et al.. (2022). A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).. Journal of Clinical Oncology. 40(4_suppl). 280–280. 4 indexed citations

10.

Ureshino, Hiroshi, Hiroo Katsuya, Yasushi Kubota, et al.. (2021). Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. International Journal of Hematology. 114(2). 199–204. 4 indexed citations

11.

Miyazato, Paola, Hiroo Katsuya, Saiful Islam, et al.. (2019). HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus. Scientific Reports. 9(1). 12326–12326. 33 indexed citations

12.

Katsuya, Hiroo, Lucy Cook, Aileen Rowan, et al.. (2018). Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomarker Research. 6(1). 24–24. 22 indexed citations

13.

Katsuya, Hiroo & Kenji Ishitsuka. (2017). Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. Journal of Clinical and Experimental Hematopathology. 57(3). 87–97. 25 indexed citations

14.

Satou, Yorifumi, Hiroo Katsuya, Naoko Misawa, et al.. (2017). Dynamics and mechanisms of clonal expansion of HIV-1-infected cells in a humanized mouse model. Scientific Reports. 7(1). 6913–6913. 21 indexed citations

15.

Miyazato, Paola, Misaki Matsuo, Hiroo Katsuya, & Yorifumi Satou. (2016). Transcriptional and Epigenetic Regulatory Mechanisms Affecting HTLV-1 Provirus. Viruses. 8(6). 171–171. 22 indexed citations

16.

Ishitsuka, Kenji, Hiroo Katsuya, Yasushi Takamatsu, et al.. (2015). Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. International Journal of Hematology. 102(4). 493–497. 9 indexed citations

17.

Nakano, Daisuke, Kenji Ishitsuka, Hiroo Katsuya, et al.. (2012). Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (II): apoptosis of antiproliferactive principle (24,25-dihydrowithanolide D) against ATL cell lines and structure–activity relationships with withanolides isolated from solanaceous plants. Journal of Natural Medicines. 67(2). 415–420. 13 indexed citations

18.

Ishitsuka, Kenji, Hiroo Katsuya, Chie Ishikawa, et al.. (2011). Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Letters. 317(2). 218–225. 29 indexed citations

19.

Katsuya, Hiroo, Tohru Takata, Takahiko Ishikawa, et al.. (2009). A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus. Journal of Infection and Chemotherapy. 15(1). 39–41. 17 indexed citations

20.

Katsuya, Hiroo, Junji Suzumiya, Hidenori Sasaki, et al.. (2009). Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leukemia & lymphoma. 50(11). 1818–1823. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact